Antibe Therapeutics Inc. (OTCMKTS: ATBPF) Brief Interest Update
Antibe Therapeutic Inc. (OTCMKTS: ATBPF – Get a rating) saw strong growth in short-term interest in April. As of April 15, there were short interests totaling 46,100 shares, up 45.9% from the total of 31,600 shares as of March 31. Based on an average daily trading volume of 12,500 shares, the short-term interest rate ratio is currently 3.7 days.
ATBPF opened at $0.56 on Friday. Antibe Therapeutics has a one-year low of $0.44 and a one-year high of $3.70. The stock’s fifty-day moving average is $0.59 and its 200-day moving average is $0.60. The company has a market capitalization of $29.07 million, a PE ratio of -1.33 and a beta of 0.22.
Therapeutic Antibe (OTCMKTS: ATBPF – Get a rating) last released its quarterly earnings data on Monday, February 14. The company reported ($0.08) EPS for the quarter, beating the Zacks consensus estimate of ($0.13) by $0.05. Antibe Therapeutics had a negative return on equity of 42.02% and a negative net margin of 244.59%. Research analysts expect Antibe Therapeutics to post -0.33 earnings per share for the current fiscal year.
Antibe Therapeutics Company Profile (Get a rating)
Antibe Therapeutics Inc, a biotechnology company, creates, develops and licenses new patented therapeutic and medical devices in the fields of pain, inflammation and regenerative medicine in Canada, Europe, the United States and abroad. Its drugs are designed to prevent gastrointestinal damage and bleeding caused by nonsteroidal anti-inflammatory drugs.
Get news and reviews for Antibe Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Antibe Therapeutics and related companies with MarketBeat.com’s free daily email newsletter.